PharmD Info

A forum for Indian Pharmacy Professionals

Important: Register today to have the complete access on this forum --- Register Here
It's an inter-professional learning platform for the doctors and other healthcare professionals to discuss on various healthcare related issues and views with pharmacy professionals. We request the doctors to raise your questions on this section. e.g. Drug Information, Decision Analysis and EBM.
Forum rules: The contents of the pharmdinfo.com, such as text, graphics, images, and other material contained on the pharmdinfo.com Site ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Pharmdinfo.com Site!

If you think you may have a medical emergency, call your doctor or 108 immediately. pharmdinfo.com does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site
#1263
Dermatology
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis, Approved March 2016

Family Medicine
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016

Hematology
Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein); CSL Behring; For the treatment of hemophilia B, Approved March 2016

Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016

Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Hepatology (Liver, Pancreatic, Gall Bladder)
Defitelio (defibrotide sodium); Jazz Pharmaceuticals; For the treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following HSCT, Approved March 2016

Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016

Immunology
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016

Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis, Approved March 2016

Infections and Infectious Diseases
Anthim (obiltoxaximab); Elusys Therapeutics; For the treatment of inhalational anthrax , Approved March 2016

Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016

Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016

Nephrology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016

Neurology
Briviact (brivaracetam); UCB; For the treatment of partial onset seizures related to epilepsy, Approved February 2016

Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease, Approved April 2016

Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016

Oncology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016

Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Pediatrics/Neonatology
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016

Pulmonary/Respiratory Diseases
Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca; For the treatment of chronic obstructive pulmonary disease, Approved April 2016

Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe asthma, Approved March 2016
Similar Topics
Topics Statistics Last post
0 Replies 
585 Views
by Admin
27 Jul 2018, 09:57
0 Replies 
292 Views
by Admin
28 Dec 2018, 16:39
0 Replies 
928 Views
by Admin
05 Oct 2017, 07:02
Pharma's Year in Review - 2018
by Admin  - 12 Dec 2018, 09:35  - In: Pharma News
0 Replies 
358 Views
by Admin
12 Dec 2018, 09:35
Pharma 2017: One Year in Review
by Krishna K  - 26 Dec 2017, 13:29  - In: Pharma Magazine
0 Replies 
986 Views
by Krishna K
26 Dec 2017, 13:29

Tags

The following information is intended to serve as […]

RSMSSB Pharmacist Recruitment 2018

for all Latest railway jobs recruitment notifica[…]

There is vacancy at Geethanjali College of Pharma[…]

Mobile app “KSPCDIC” version 3.0 is no[…]

WELCOME TO OUR E-LEARN COURSE WORK MODULES